

Metro Center for High Technology Bldg. 2727 Second Ave. Suite 4113

Detroit, MI 48201 Tel: 313.961.1606 Fax: 313.963.7130

Email: info@detroitrandd.com www.detroitrandd.com

Safety Data Sheet

Version 1.2

Section 1. Product and Company Identification

1.1 Product Identifiers:

Product Name: 8-Isoprostane Oxidative Stress Urinary ELISA kit

Product Number: 8iso1U and 8iso1UR

1.2 Relevant identified uses of the substance or mixture and uses advised against Identified

uses: Laboratory chemicals, Manufacture of substances 1.3 Details of the supplier of the safety data sheet

1.3 Details of the Supplier of the Safety Data Sheet:

Detroit R&D, Inc.

2727 Second Ave. Suite 4113

Detroit, MI 48201

Tel: 313.961.1606 Fax: 313.963.7130

1.4 Emergency telephone number: 313.963.7130

This is a summary SDS for a kit.

Section 2. Hazards Identification:

2.1 Classification of the substance or mixture: Not hazardous.

The chemical, physical, and toxicological properties of the above components have not been extensively studied. Normal laboratory safety procedures should be adhered to when handling the product or the components contained within, avoid direct physical contact wherever possible.

2.2 GHS label elements: Not hazardous

2.3 Hazards not otherwise classified (HNOC) or not covered by GHS: None

Detroit R&D, Inc. Page 1 of 4

Section 3. Composition Information :

Description	Quantity
8-isoprostane IgG coated plate	1 each
8-isoprostane Standard	$2 \mu L$
8-isoprostane/HRP enzyme conjugates	12 μL
HRP Buffer (1X)	15 μL
Sample Dilution Buffer (10X)	25 mL
Wash Buffer (10X)	25 mL
TMB Substrate	24 mL
Beta glucuronidase enzyme	8 mg
Stop Solution (0.8 MOL/L sulfuric acid)	5 mL

The above listed components are intended for research use only. GSH Classification: No data available

Section 4. First Aid Measures

Ingestion: Provided the person is conscious, wash out mouth with water. Seek medical attention immediately. Do not induce vomiting unless directed by medical personnel. **Inhalation**: Remove person to fresh air. If breathing becomes difficult or stops, administer oxygen or artificial respiration via trained personnel. Seek immediate medical attention.

Skin Contact: Immediately remove any contaminated clothing and wash affected area extensively with soap and water. If symptoms ensue seek medical attention. **Eye Contact**: Separate eyelids, remove any contact lenses present and flush eyes with ample amounts of water for a minimum of 15 minutes. Seek medical attention.

SULFURIC ACID IF SWALLOWED, WASH OUT MOUTH WITH WATER PROVIDED PERSON IS CONSCIOUS. CALL A PHYSICIAN IMMEDIATELY. DO NOT INDUCE VOMITING. IF INHALED, REMOVE TO FRESH AIR. IF NOT BREATHING GIVE ARTIFICIAL RESPIRATION. IF BREATHING IS DIFFICULT, GIVE OXYGEN. IN CASE OF SKIN CONTACT, FLUSH WITH COPIOUS AMOUNTS OF WATER FOR AT LEAST 15 MINUTES. REMOVE CONTAMINATED CLOTHING AND SHOES. CALL A PHYSICIAN. IN CASE OF CONTACT WITH EYES, FLUSH WITH COPIOUS AMOUNTS OF WATER FOR AT LEAST 15 MINUTES. ASSURE ADEQUATE FLUSHING BY SEPARATING THE EYELIDS WITH FINGERS. CALL A PHYSICIAN.

Section 5. Fire Fighting Measures: The components included in this product pose no major risk of fire. If one does occur, use appropriate extinguishing media.

Detroit R&D, Inc. Page 2 of 4

Section 6. Accidental Release Measures: Wear appropriate protective gear. Absorb the spill with an inert material and dispose of according to proper regulations. Ventilate the contaminated area and wash down the area with soap and water.

Section 7. Handling and Storage: Store all components in closed containers and at the correct temperature, as specified by the component label (and spec sheet). Wear gloves and avoid physical contact if possible. Wash hands after handling.

Section 8. Exposure Controls/Personal Protection: No data. Normal laboratory safety procedures should be adhered to when handling the product or the components contained within, avoid direct physical contact wherever possible

Section 9. Physical and chemical properties:

Description	Physical State	Appearance
8-isoprostane IgG coated plate	Dry, solid	clear
8-isoprostane Standard	liquid	Clear solution
8-isoprostane/HRP enzyme conjugates	liquid	Clear solution
HRP Buffer (1X)	liquid	Clear solution
Sample Dilution Buffer (10X)	liquid	Clear solution
Wash Buffer (10X)	liquid	Clear solution
TMB Substrate	liquid	Clear solution
Stop Solution (0.8 MOL/L sulfuric acid)	liquid	Clear solution

Section 10. Stability and Reactivity: Given the correct storage procedures are followed, the components are stable until the listed expiration date.

Description	Stability
8-isoprostane IgG coated plate	Stable at 4°C or less
8-isoprostane Standard	Stable at -20°C or less
8-isoprostane/HRP enzyme conjugates	Stable at 4°C or less
HRP Buffer (1X)	Stable at 4°C or less
Sample Dilution Buffer (10X)	Stable at 4°C or less
Wash Buffer (10X)	Stable at 4°C or less
TMB Substrate	Stable at 4°C or less
Stop Solution (0.8 MOL/L sulfuric acid)	Stable at 4oC or less

Section 11. Toxicological Information: The toxicological effects of these components have not been extensively studied.

SULFURIC ACID ACUTE EFFECTS: CAUSES BURNS, MAY BE HARMFUL IF ABSORBED THROUGH THE SKIN, MATERIAL IS EXTREMELY DESTRUCTIVE TO THE TISSUE OF THE MUCOUS MEMBRANES AND UPPER RESPIRATORY TRACT, TOXIC IF INHALED, MAY BE HARMFUL IF SWALLOWED, MATERIAL IS EXTREMELY DESTRUCTIVE TO TISSUE OF THE MUCOUS MEMBRANES AND UPPER RESPIRATORY TRACT, EYES AND SKIN, INHALATION MAY RESULT IN SPASM,

Detroit R&D, Inc. Page 3 of 4

INFLAMMATION AND EDEMA OF THE LARYNX AND BRONCHI, CHEMICAL PNEUMONITIS AND PULMONARY EDEMA. SYMPTOMS OF EXPOSURE MAY INCLUDE BURNING SENSATION, COUGHING, WHEEZING, LARYNGITIS, SHORTNESS OF BREATH, HEADACHE, NAUSEA AND THE ABOVE INFORMATION IS BELIEVED TO BE CORRECT BUT IS NOT NECESSARILY ALL-INCLUSIVE AND SHOULD BE USED ONLY AS A GUIDE. DETROIT R&D. SHALL NOT BE HELD LIABLE FOR ANY DAMAGE RESULTING FROM HANDLING OR FROM CONTACT WITH THE ABOVE PRODUCT. INDIVIDUALS RECEIVING THE INFORMATION MUST EXERCISE THEIR INDEPENDENT JUDGMENT IN DETERMINING ITS APPROPRIATENESS FOR A PARTICULAR PURPOSE. VOMITING. TO THE BEST OF OUR KNOWLEDGE, THE CHEMICAL, PHYSICAL, AND TOXICOLOGICAL PROPERTIES HAVE NOT BEEN THOROUGHLY INVESTIGATED. CHRONIC EFFECTS: THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER (IARC) HAS DETERMINED THAT OCCUPATIONAL EXPOSURE TO STRONG-INORGANIC-ACID MISTS CONTAINING SULFURIC ACID IS CARCINOGENIC TO HUMANS (GROUP 1). TARGET ORGAN(S): TEETH, CARDIOVASCULAR SYSTEM RTECS #: WS5600000 SULFURIC ACID IRRITATION DATA: EYE-RBT 250 UG SEV AJOPAA 29,1363,1946 EYE-RBT 5 MG/30S RINSE SEV TXCYAC 23,281,1982 TOXICITY DATA: UNR-MAN LDLO:135 MG/KG 85DCAI 2,73,1970 ORL-RAT LD50:2140 MG/KG AIHAAP 30,470,1969 IHL-RAT LC50:510 MG/M3/2H 85GMAT -,107,1982 IHL-MUS LC50:320 MG/M3/2H 85GMAT -,107,1982 IHL-GPG LC50:18 MG/M3 MELAAD 45,590,1954 ONLY SELECTED REGISTRY OF TOXIC EFFECTS OF CHEMICAL SUBSTANCES (RTECS) DATA IS PRESENTED HERE

Section 12. Ecological Information: No data available.

Section 13. Disposal Considerations: Dispose in accordance to all Federal, State, and Local regulations.

Section 14. Transportation:

TRANSPORT INFORMATION OVERLAND TRANSPORTATION (ADR/RID): AS A MIXTURE, THE SUBSTANCE IS SUBJECT TO NO LIMITATIONS

TRANSATLANTIC TRANSPORTATION (IMDG): AS A MIXTURE, THE SUBSTANCE IS SUBJECT TO NO LIMITATIONS

AIR TRANSPORTATION (ICAO/IATA): AS A MIXTURE, THE SUBSTANCE IS SUBJECT TO NO LIMITATIONS

Section 15. Regulatory Information: None.

Section 16. Other Information: This document was prepared on 07/06/2015 and conforms with US OSHA Hazard Communication Standard 29 CFR 1910 1200

Detroit R&D, Inc. Page 4 of 4